{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T16:12:11Z","timestamp":1783959131682,"version":"3.55.0"},"reference-count":41,"publisher":"The Journal of Rheumatology","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Rheumatol"],"accepted":{"date-parts":[[2025,8,17]]},"published-print":{"date-parts":[[2026,2]]},"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>Secondary failure to biologic disease-modifying antirheumatic drugs (bDMARDs) is challenging and contributes to the complexity of managing psoriatic arthritis (PsA). We aimed to define the frequency and incidence of this phenomenon in PsA and identify the risk factors for its occurrence.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We retrieved data on patients with PsA from our single-center, specialized-care, prospective observational cohort who initiated and remained on bDMARDs for \u2265 1 year after clinic enrollment between 2000 and 2023. We defined response to therapy at the 1-year visit (baseline) as achievement of \u2265 40% reduction in the swollen joint count (SJC) and either \u2265 50% reduction in Psoriasis Area and Severity Index (PASI) or PASI \u2264 2. We defined secondary failure as the inability to maintain response criteria or as the clinician\u2019s judgment of loss of effectiveness. To examine factors associated with secondary failure, we fitted Cox regression models.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Of 482 patients included in the study, 264 (54.8%) were responders at 1 year. Of these, 94 (35.6%) developed secondary failure at a median of 1.6 (IQR 0.7-3.8) years from response. In the multivariable model, higher SJC (hazard ratio [HR] 1.39, 95% CI 1.05-1.84) and PASI (HR 1.14, 95% CI 1.01-1.29) at baseline were associated with secondary failure. Tumor necrosis factor inhibitors (TNFi) vs other bDMARD use (HR 0.39, 95% CI 0.18-0.88), initiation as first-line bDMARD (HR 0.48, 95% CI 0.25-0.91), and treatment initiation during more recent calendar years (HR 0.34, 95% CI 0.12-0.98) were associated with less secondary failure.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Secondary failure to bDMARD is common in PsA and may be influenced by both disease- and therapy-related factors.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3899\/jrheum.2025-0518","type":"journal-article","created":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T12:20:20Z","timestamp":1756729220000},"page":"162-169","source":"Crossref","is-referenced-by-count":2,"title":["Incidence and Predictors of Secondary Failure to Biologic Therapy in Patients With Psoriatic Arthritis"],"prefix":"10.3899","volume":"53","author":[{"given":"Fadi","family":"Kharouf","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali","family":"AlHadri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shangyi","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Pereira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard J.","family":"Cook","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vinod","family":"Chandran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9074-0592","authenticated-orcid":false,"given":"Dafna D.","family":"Gladman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2262","published-online":{"date-parts":[[2025,9,1]]},"reference":[{"key":"2026070105051076000_53.2.162.1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1505557"},{"key":"2026070105051076000_53.2.162.2","doi-asserted-by":"publisher","DOI":"10.1038\/s41584-022-00798-0"},{"key":"2026070105051076000_53.2.162.3","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1002\/art.40726","article-title":"Special article: 2018 American College of Rheumatology\/National Psoriasis Foundation guideline for the treatment of psoriatic arthritis","volume":"71","author":"Singh","year":"2019","journal-title":"Arthritis Rheumatol"},{"key":"2026070105051076000_53.2.162.4","doi-asserted-by":"publisher","DOI":"10.1136\/ard-2024-225531"},{"key":"2026070105051076000_53.2.162.5","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2017.02.001"},{"key":"2026070105051076000_53.2.162.6","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2021-220202"},{"key":"2026070105051076000_53.2.162.7","doi-asserted-by":"publisher","DOI":"10.1159\/000478077"},{"key":"2026070105051076000_53.2.162.8","doi-asserted-by":"publisher","DOI":"10.1016\/j.berh.2011.10.004"},{"key":"2026070105051076000_53.2.162.9","doi-asserted-by":"publisher","DOI":"10.1007\/s40259-017-0231-8"},{"key":"2026070105051076000_53.2.162.10","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.190116"},{"key":"2026070105051076000_53.2.162.11","doi-asserted-by":"crossref","first-page":"1759720X211002685","DOI":"10.1177\/1759720X211002685","article-title":"Impact of immunogenicity on clinical efficacy and toxicity profile of biologic agents used for treatment of inflammatory arthritis in children compared to adults","volume":"13","author":"Parikh","year":"2021","journal-title":"Ther Adv Musculoskelet Dis"},{"key":"2026070105051076000_53.2.162.12","doi-asserted-by":"crossref","first-page":"711","DOI":"10.2340\/00015555-2069","article-title":"Risk factor analysis for the immunogenicity of adalimumab associated with decreased clinical response in Chinese patients with psoriasis","volume":"95","author":"Chiu","year":"2015","journal-title":"Acta Derm Venereol"},{"key":"2026070105051076000_53.2.162.13","doi-asserted-by":"crossref","first-page":"rkaa070","DOI":"10.1093\/rap\/rkaa070","article-title":"Persistence of biologic treatments in psoriatic arthritis: a population-based study in Sweden","volume":"4","author":"Geale","year":"2020","journal-title":"Rheumatol Adv Pract"},{"key":"2026070105051076000_53.2.162.14","doi-asserted-by":"publisher","DOI":"10.1186\/s13075-021-02417-x"},{"key":"2026070105051076000_53.2.162.15","doi-asserted-by":"publisher","DOI":"10.1002\/acr.25112"},{"key":"2026070105051076000_53.2.162.16","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kex387"},{"key":"2026070105051076000_53.2.162.17","first-page":"34","article-title":"Retention on anti-tumour necrosis factor therapy: the Waikato experience","volume":"128","author":"Ip","year":"2015","journal-title":"N Z Med J"},{"key":"2026070105051076000_53.2.162.18","doi-asserted-by":"publisher","DOI":"10.1186\/ar2670"},{"key":"2026070105051076000_53.2.162.19","doi-asserted-by":"publisher","DOI":"10.1002\/art.30117"},{"key":"2026070105051076000_53.2.162.20","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2007.073544"},{"key":"2026070105051076000_53.2.162.21","doi-asserted-by":"publisher","DOI":"10.1002\/art.21972"},{"key":"2026070105051076000_53.2.162.22","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/37.7.760"},{"key":"2026070105051076000_53.2.162.23","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780270401"},{"key":"2026070105051076000_53.2.162.24","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keq262"},{"key":"2026070105051076000_53.2.162.25","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keq091"},{"key":"2026070105051076000_53.2.162.26","doi-asserted-by":"publisher","DOI":"10.1002\/acr.22529"},{"key":"2026070105051076000_53.2.162.27","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2015-207507"},{"key":"2026070105051076000_53.2.162.28","first-page":"886","article-title":"Measuring health status in psoriatic arthritis: the Health Assessment Questionnaire and its modification","volume":"22","author":"Blackmore","year":"1995","journal-title":"J Rheumatol"},{"key":"2026070105051076000_53.2.162.29","doi-asserted-by":"crossref","unstructured":"Kalbfleisch JD , Prentice RL. The statistical analysis of failure time data. Chichester, UK: John Wiley & Sons; 2002.","DOI":"10.1002\/9781118032985"},{"key":"2026070105051076000_53.2.162.30","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1007\/s00296-021-04928-x","article-title":"Long-term survival of biological therapy in psoriatic arthritis: 18-year analysis of a cohort in a tertiary hospital","volume":"42","author":"Mateo Soria","year":"2022","journal-title":"Rheumatol Int"},{"key":"2026070105051076000_53.2.162.31","doi-asserted-by":"crossref","first-page":"3397","DOI":"10.1007\/s10067-023-06760-z","article-title":"Long-term golimumab persistence: five-year treatment retention data pooled from pivotal phase III clinical trials in patients with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis","volume":"42","author":"Weinstein","year":"2023","journal-title":"Clin Rheumatol"},{"key":"2026070105051076000_53.2.162.32","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1186\/s13075-025-03518-7","article-title":"Burden and determinants of multi-b\/tsDMARD failure in psoriatic arthritis","volume":"27","author":"Haberman","year":"2025","journal-title":"Arthritis Res Ther"},{"key":"2026070105051076000_53.2.162.33","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2022-002681"},{"key":"2026070105051076000_53.2.162.34","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1001\/jamadermatol.2022.0364","article-title":"Long-term persistence of first-line biologics for patients with psoriasis and psoriatic arthritis in the French health insurance database","volume":"158","author":"Pina Vegas","year":"2022","journal-title":"JAMA Dermatol"},{"key":"2026070105051076000_53.2.162.35","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2007.082925"},{"key":"2026070105051076000_53.2.162.36","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2012-203018"},{"key":"2026070105051076000_53.2.162.37","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-017-3593-x"},{"key":"2026070105051076000_53.2.162.38","doi-asserted-by":"publisher","DOI":"10.7861\/clinmedicine.14-1-95"},{"key":"2026070105051076000_53.2.162.39","doi-asserted-by":"crossref","first-page":"3035","DOI":"10.1007\/s10067-022-06218-8","article-title":"Efficacy and safety of ixekizumab in patients with active psoriatic arthritis with and without concomitant conventional disease-modifying antirheumatic drugs: SPIRIT-P1 and SPIRIT-P2 3-year results","volume":"41","author":"Coates","year":"2022","journal-title":"Clin Rheumatol"},{"key":"2026070105051076000_53.2.162.40","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2015-000181"},{"key":"2026070105051076000_53.2.162.41","doi-asserted-by":"crossref","first-page":"e3015","DOI":"10.6061\/clinics\/2021\/e3015","article-title":"Immunogenicity to biological drugs in psoriasis and psoriatic arthritis","volume":"76","author":"Valenzuela","year":"2021","journal-title":"Clinics"}],"container-title":["The Journal of Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.3899\/jrheum.2025-0518","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T12:13:38Z","timestamp":1782908018000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.jrheum.org\/lookup\/doi\/10.3899\/jrheum.2025-0518"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,1]]},"references-count":41,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2026,2,1]]},"published-print":{"date-parts":[[2026,2]]}},"alternative-id":["10.3899\/jrheum.2025-0518"],"URL":"https:\/\/doi.org\/10.3899\/jrheum.2025-0518","relation":{},"ISSN":["0315-162X","1499-2752"],"issn-type":[{"value":"0315-162X","type":"print"},{"value":"1499-2752","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,1]]}}}